Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer
Executive Summary
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
You may also be interested in...
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.
Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data
Clinicians and the company have heralded the IMpassion130 data presented at ESMO which showed that Roche's Tecentriq is the first immunotherapy to improve outcomes in TNBC but a slight blot on the landscape is that pretty much all of the survival benefit was seen in breast cancer patients with PD-L1 positive tumors.
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.